EPRX fundamentals
An in-depth look to Eupraxia Pharmaceuticals Inc. operating, investing, and financing activities
EPRX free cash flow for Q1 24 is -6.1 M USD. For 2023, EPRX free cash flow was -21.14 M USD and operating cash flow was -21.06 M USD.
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q1 '24
TTM